Strong traction in India and the US market and launches of new products including Revlimid aided the growth in revenue however rise in cost eroded Margins | Zydus Lifesciences Q2 FY23 Result & Earning Call Highlights

Published on 15 November 2022
.Views 6 .Comments 0

Share On